Publications

Original articles

Di Marco GS, Beul K, Bormann E, Pavenstädt H, Brand M. Endothelial biomarkers predict renal and cardiovascular outcomes after acute kidney injury. Clin Kidney J. 2026; 19(9):sfag277.

Kühne L, Osterholt T, Suer M, Cukoski S, Wendt R, Pfrepper C, Petros S, Schönermarck U, von Bergwelt-Baildon A, Kaufeld J, Gäckler A, Schönfelder K, Seibert FS, Masla M, Bramstedt J, Schwenger V, Seelow E, Mühlfeld A, Bommer M, Schmidt T, Brand M, Walendy V, Schulte-Kemna L, Thaler J, Eller K, Ruhe J, Jabs WJ, Elitok S, Hart C, Eisinger F, Nitschke M, Grasshoff L, Miesbach W, Özcan F, Eichenauer DA, Menne J, Knöbl P, Völker LA, Brinkkoetter PT. Revisiting clinical response and refractoriness in immune thrombotic thrombocytopenic purpura. Blood. 2026; 147(21):2463-2471.

Di Marco GS, Chasan AI, Boeckel GR, Beul K, Pavenstädt H, Roth J, Brand M. Monocytes as Targets for Immunomodulation by Regional Citrate Anticoagulation. Int J Mol Sci. 2024; 25(5):2900. 

Schulz A, Drost CC, Hesse B, Beul K, Boeckel GR, Lukasz A, Pavenstädt H, Brand M, Di Marco GS. The Endothelial Glycocalyx as a Target of Excess Soluble Fms-like tyrosine kinase-1. Int J Mol Sci. 2023; 24(6):5380. 

Eltayeb SA, Ciarimboli G, Beul K, Di Marco GS, Barz V. Role of Organic Cation Transporter 2 in Autophagy Induced by Platinum Derivatives. Int J Mol Sci. 2022; 23(3):1090. 

Pfeuffer S, Rolfes L, Wirth T, Steffen F, Pawlitzki M, Schulte-Mecklenbeck A, Gross CC, Brand M, Bittner S, Ruck T, Klotz L, Wiendl H, Meuth SG. Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. J Neuroinflammation. 2022;19(1):220.

Schulz A, Drost CC, Hesse B, Beul K, Brand M, Di Marco GSThe soluble Fms-like tyrosine kinase-1 contributes to structural and functional changes in endothelial cells in chronic kidney disease. Int J Mol Sci. 2022; 23(24):16059. 

Bücker P, Richter H, Radbruch A, Sperling M, Brand M, Holling M, Van Marck V, Paulus W, Jeibmann A, Karst U. Deposition patterns of iatrogenic lanthanum and gadolinium in the human body depend on delivered chemical binding forms. J Trace Elem Med Biol. 2021; 63:126665.

Hesse B, Rovas A, Buscher K, Kusche-Vihrog K, Brand MDi Marco GS, Kielstein JT, Pavenstädt H, Linke WA, Nofer JR, Kümpers P, Lukasz A. Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease. Kidney Int. 2020; 97(3):502-515

Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020; 4(13):3085-3092.

Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with a TTP. Blood Adv. 2020; 4(13):3093-3101

Wewers TM, Mayer AB, Pfleiderer A, Beul K, Schmidt R, Heitplatz B, Van Marck V, Nolte I, Pavenstädt H, Reuter S, Brand MDi Marco GSIncreased soluble fms-like tyrosine kinase 1 after ischemia-reperfusion contributes to adverse clinical outcomes following kidney transplantation. Kidney Int. 2019; 95(5):1091-1102. 

Pfeuffer S, Rolfes L, Bormann E, Sauerland C, Ruck T, Schilling M, Melzer N, Brand M, Pul R, Kleinschnitz C, Wiendl H, Meuth SG. Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. J Clin Med. 2019; 9(1):35.

Thölking G, Schuette-Nuetgen K, Vogl T, Dobrindt U, Kahr BC, Brand M, Pavenstädt H, Suwelack B, Koch R, Reuter S. Male kidney allograft recipients at risk for urinary tract infection? PLoS One. 2017;12(11)e0188262

Golle L, Gerth HU, Beul K, Heitplatz B, Barth P, Fobker M, Pavenstädt H, Di Marco GS, Brand MBone marrow-derived cells and their conditioned medium induce microvascular repair in uremic rats by stimulation of endogenous repair mechanisms.Sci Rep. 2017; 7(1):9444. 

Grabner A, Schramm K, Silswal N, Hendrix M, Yanucil C, Czaya B, Singh S, Wolf M, Hermann S, Stypmann J, Di Marco GS, Brand M, Wacker MJ, Faul C. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.Sci Rep. 2017; 7(1):1993. 

Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.Kidney Int. 2016; 90(5):985-996.

Dogan Onugoren M, Golombeck KS, Bien C, Abu-Tair M, Brand M, Bulla-Hellwig M, Lohmann H, Münstermann D, Pavenstädt H, Thölking G, Valentin R, Wiendl H, Melzer N, Bien CG. Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm. 2026;3(2)e207 

Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.Cell Metab. 2015;22(6):1020-1032.

Di Marco GS, Kentrup D, Reuter S, Mayer AB, Golle L, Tiemann K, Fobker M, Engelbertz C, Breithardt G, Brand E, Reinecke H, Pavenstädt H, Brand MSoluble Flt-1 links microvascular disease with heart failure in CKD.Basic Res Cardiol. 2015; 110(3):30. 

Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, Shelton J, Amaral AP, Faul C, Taniguchi M, Wolf M, Brand M, Takahashi M, Kuro-O M, Hill JA, Moe OW: Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.J Am Soc Nephrol. 26(6):1290-302, 2015. 

Di Marco GS, Reuter S, Kentrup D, Grabner A, Amaral AP, Fobker M, Stypmann J, Pavenstädt H, Wolf M, Faul C, Brand MTreatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant. 2014; 29(11):2028-2035.

Padberg JS, Wiesinger A, Di Marco GS, Reuter S, Grabner A, Kentrup D, Lukasz A, Oberleithner H, Pavenstädt H, Brand M, Kümpers P. Damage of the endothelial glycocalyx in chronic kidney disease.Atherosclerosis. 2014; 234(2):335-343.

Di Marco GS*, König M*, Stock C, Wiesinger A, Hillebrand U, Reiermann S, Reuter S, Amler S, Köhler G, Buck F, Fobker M, Kümpers P, Oberleithner H, Hausberg M, Lang D, Pavenstädt H, Brand MHigh phosphate directly affects endothelial function by downregulating annexin II. Kidney Int. 2013; 83(2):213-22. 

Bartels V, Hillebrand U, Kosch M, Hausberg M, Kisters K, Di Marco GS, Reiermann S, Pavenstaedt H, Lang D. Influence of erythropoietin on arterial stiffness and endothelial function in renal transplant recipients.Am J Nephrol. 2012;36(4):355-61.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy.J Clin Invest. 2011;121(11):4393-408.

Di Marco GS*, Rustemeyer P*, Brand M, Koch R, Kentrup D, Grabner A, Greve B, Wittkowski W, Pavenstädt H, Hausberg M, Reuter S, Lang D. Circulating endothelial progenitor cells in kidney transplant patients. PLoS One. 2011;6(9):e24046.

Di Marco GS*, Reuter S*, Kentrup D, Ting L, Ting L, Grabner A, Jacobi AM, Pavenstädt H, Baba HA, Tiemann K, Brand M. Cardioprotective effect of calcineurin inhibition in an animal model of renal disease. Eur Heart J. 2011;32(15):1935-45.

Hsu HH, Hoffmann S, Di Marco GS, Endlich N, Peter-Katalinić J, Weide T, Pavenstädt H. Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis. Kidney Int. 2011;80(9):959-69.

Colucci JA, Arita DY, Cunha TS, Di Marco GS, Vio CP, Pacheco-Silva A, Casarini DE. Renin-angiotensin system may trigger kidney damage in NOD mice.J Renin Angiotensin Aldosterone Syst. 2011;12(1):15-22.

Di Marco GS, Reuter S, Hillebrand U, Amler S, König M, Larger E, Oberleithner H, Brand E, Pavenstädt H, Brand M. Soluble VEGF receptor Flt1 (sFlt-1) contributes to endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2009;20(10):2235-45. 

Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D, Pavenstädt H. Inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol. 2008;294(6):F1381-7.

Di Marco GS, Alam A, Dol G, Corvol P, Gasc JM, Larger E. Angiogenesis and Diabetes: different responses to pro-angiogenic factors in the chorioallantoic membrane assay. Mol Med. 2008;14(11-12):705-14. 

Brand M, Lamandé N, Larger E, Corvol P, Gasc JM. Angiotensinogen impairs angiogenesis in the chick chorioallantoic membrane. J Mol Med (Berl); 85(5):451-60, 2007.

Brand M, Lamandé N, Sigmund CD, Larger E, Corvol P, Gasc JM. Angiotensinogen modulates renal vasculature growth. Hypertension; 47(6):1067-74, 2006.

Brand M, Le Moullec JM, Corvol P, Gasc JM: Ontogeny of endothelins-1 and -3, their receptors, and endothelin-converting enzyme-1 in the early human embryo. J Clin Invest. 101:549-59. 1998.

 

Reviews 

Koschmieder S, Brand M, Kremer AE. Systemischer Pruritus: hämatologische, nephrogene und hepatobiliäre Ursachen im Fokus. Die Dermatologie. 2026; 77(7):433–440.

Brand M, Kremer AE. Systemic pruritus: what is new in diagnosis and treatment? Dermatologie. 2022;73(8)600-608.

Wewers TM, Schulz A, Nolte I, Pavenstädt H, Brand MDi Marco GSCirculating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia. J Am Soc Nephrol. 2021; 32(8):1853-1863. 

Deharde D, Klockenbusch W, Schmitz R, Brand M, Köster HA, de KO. Hydroxychloroquine as a Preventive and Therapeutic Option in Preeclampsia – a Literature Review. Geburtshilfe Frauenheilkd. 2020; 80(7):679-685.

Rolfes L, Pfeuffer S, Ruck T, Melzer N, Pawlitlzki M, Heming M, Brand M, Wiendl H, Meuth SG. Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Need-A Systematic Review. J Clin Med. 2019; 8(10):1623. 

Di Marco GS, Brand M. Off-target effects and adverse outcomes of fibroblast growth factor 23 in chronic kidney disease. Port J Nephrol Hypert. 2018; 32(1):57-63. 

Phosphatregulation und kardiovaskuläre Konsequenzen – Was ist bei chronisch nierenerkrankten Patienten zu beachten? Brand M, Di Marco GS, Pavenstädt H. Dialyse aktuell 2015;19(S01):s6-s10

 

Editorials, Letters, Comments 

Di Marco GS, Pavenstädt H, Brand M. Soluble Flt-1 release response to heparin use: implications for dialysis patients? Nephrol Dial Transplant. 2014;29(6):1112-5. 

Di Marco GS, Brand MLetter by Di Marco and Brand regarding the article, Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis.Circulation. 2010;122(5):e416; athor reply e417. 

 

Cases Reports 

Krakow M, Hinrichs JH, Horvath J, Pavenstädt H, Brand M. Atypical Hemolytic Uremic Syndrome/Complement-Mediated Thrombotic Microangiopathy Triggered by SARS-CoV-2 Infection: A Case Report. Case Rep Nephrol Dial. 2025;15(1):119-124